

Cite this as: Jun ZHU, Rong-jun GAO, Qiang LIU, Ru-hong JIANG, Lu YU, Ya-xun SUN, Pei ZHANG, Jian-wei LIN, Yang YE, Zu-wen ZHANG, Shi-quan CHEN, Hui CHENG, Xia SHENG, Chen-yang JIANG, 2017. Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation. *Journal of Zhejiang University-Science B (Biomedicine & Biotechnology)*, 18(11):946-954.
<http://dx.doi.org/10.1631/jzus.B1600492>

Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation

Key words: Atrial fibrillation, Radiofrequency catheter ablation, Anticoagulation, Rivaroxaban

Research Summary

The study primarily focuses on the metabolic benefits as well as safety and efficacy of rivaroxaban administration in non-valvular patients after undergoing radiofrequency catheter ablation.

- **Metabolic benefits of rivaroxaban**
 - **Underlying reason --- less dietary restriction**
 - **Safe and effective alternative anticoagulant**



Metabolic benefits




Figure 1



Safety and efficacy endpoints

Endpoints	Rivaroxaban (n=30)	Warfarin (n=30)	Total (n=60)	P value
Safety endpoint	12 (40.0)	10 (33.3)	22 (36.7)	0.59
Major bleeding event	0 (0.0)	0 (0.0)	0 (0.0)	1.00
Overt bleeding event	0 (0.0)	2 (6.7)	2 (3.3)	0.15
Groin hematoma	0 (0.0)	1 (3.3)	1 (1.7)	0.31
Increased menstruation	0 (0.0)	1 (3.3)	1 (1.7)	0.31
Minor bleeding event	11 (36.7)	8 (26.7)	19 (31.7)	0.41
Dental bleeding	4 (13.3)	4 (13.3)	8 (13.3)	1.00
Hematuria	6 (20.0)	3 (10.0)	9 (15.0)	0.28
Hematochezia	1 (3.3)	1 (3.3)	2 (3.3)	1.00
Drug adverse effect	1 (3.3)	0 (0.0)	1 (1.7)	0.31
Efficacy endpoint	0 (0.0)	0 (0.0)	0 (0.0)	1.00